Press Releases

News & Media

Newport Beach, California--(Newsfile Corp. - January 7, 2020) - Vivera Pharmaceuticals, Inc., a pharmaceutical company focused on non-addictive pain management, today announces the appointment of Andrea Millsap as the Company's National Sales Director. A key aspect of her role is to develop and implement sales strategies and infrastructure for Vivera's entire sales team.

"I am thrilled to join Vivera to help increase awareness of its innovative products," said Ms. Millsap. "I look forward to using my expertise to forge strong relationships with customers and physicians across the country. I began my career within the pharmaceutical industry because of my desire to help people and I believe that Vivera's TVIA Kit® products can change the landscape when it comes to pain management."

A highly skilled sales and marketing executive, Ms. Millsap previously held positions at Pfizer Pharmaceuticals, Zila Pharmaceuticals, and Nevada Dental Associates prior to joining Vivera. At Pfizer for over eight years, Ms. Millsap was the District Product Lead for Lyrica and instrumental in the Eucrisa product launch. Appointed Lyrica Field Force Faculty, she aided in the roll out and implementation of the Lyrica brand strategy. Other responsibilities at Pfizer included promoting its product portfolio to high volume primary care offices and specialty offices to increase provider and patient awareness. An ambitious leader, Ms. Millsap was able to quickly establish rapport, build credibility and cultivate lasting relationships with major accounts during her time at both Pfizer and Zila.

"I am confident that Andrea will excel in her new role with us," said Paul Edalat, Chairman and Founder of Vivera. "She is an outstanding motivator with a proven track record of developing high-performing sales teams and creating a winning culture. Plus, she brings a unique perspective that I believe will better serve our sales force, and ultimately our customers."

"Not only have I had a successful career in pharmaceutical sales, but I recently had heart surgery and when I left the hospital, I used Vivera's products," added Ms. Millsap. "I'm living proof that the products work and I'm eager to share my experience and help Vivera make a difference. I'm excited for what the future holds."

Ms. Millsap received a Bachelor of Arts degree in Corporate Communications from the University of Nevada, Las Vegas and is a part of the Alumni Association. She was a Member of the Primary Care Performance Pillar Team in 2016. In 2016 she was also selected by her peers for the Pfizer "Own It" award, an award given for demonstrating excellence within the field and amongst fellow cohorts. Ms. Millsap was a 2015 Summit Winner, finishing the year as one of the top 10 national sales representatives in the country. She is passionate about patient advocacy and making a difference in the healthcare sector.

About Vivera Pharmaceuticals, Inc.

Vivera Pharmaceuticals, Inc. is an innovative, science-driven pharmaceutical company focused on opioid deterrence and cessation and non-addictive solutions for pain management.

In addition to its pharmaceutical and medical device products, the company has global exclusivity to license the patented and patent-pending TABMELT™ sublingual drug-delivery system for the pharmaceutical use of cannabinoid compounds.

Vivera Pharmaceuticals is seeking to conduct case studies and clinical trials on CBD in the TABMELT™ drug delivery format with the goal of gaining FDA approval for its products.

The company is vertically integrated with patented technology, manufacturing capabilities and distribution for its products.

The securities described herein, if any, have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities laws, and may not be offered or sold within the United States or to, or for the benefit of, U.S. persons (as defined in Regulation S under the U.S. Securities Act) except in compliance with the registration requirements of the U.S. Securities Act and applicable state securities laws or pursuant to exemptions therefrom. This release does not constitute an offer to sell or a solicitation of an offer to buy of any of Vivera Pharmaceuticals securities in the United States. This news release may contain "forward-looking information" as defined in applicable Canadian securities legislation. All statements other than statements of historical fact included in this release, including, without limitation, future operating margins, future production and processing, processing results, and future plans and objectives of Vivera Pharmaceuticals, constitute forward looking information that involve various risks and uncertainties. Forward-looking information is based on a number of factors and assumptions which have been used to develop such information but which may prove to be incorrect, including, but not limited to, assumptions in connection with the continuance of Vivera Pharmaceuticals and its subsidiaries as a going concern, general economic and market conditions, price of biomass, the accuracy of production resource estimates, and the performance of Vivera Pharmaceuticals future operations. There can be no assurance that such information will prove to be accurate and actual results and future events could differ materially from those anticipated in such forward-looking information. Important factors that could cause actual results to differ materially from Vivera Pharmaceuticals' expectations include but are not limited to: changes in economic conditions or financial markets; increases in costs; litigation; legislative, environmental and other judicial, regulatory, political and competitive developments; and technological or operational difficulties. This list is not exhaustive of the factors that may affect our forward-looking information. These and other factors should be considered carefully, and readers should not place undue reliance on such forward-looking information. For additional information with respect to risk factors applicable to Vivera Pharmaceuticals, reference should be made to Vivera Pharmaceuticals continuous disclosure materials filed from time to time with securities regulators, including, but not limited to, Vivera Pharmaceuticals CSE Listing Statement. The forward-looking information contained in this release is made as of the date of this release. Vivera Pharmaceuticals does not intend, and expressly disclaims any intention or obligation to update or revise any forward-looking information whether as a result of new information, future events or otherwise, except as required by applicable law. The CSE has not reviewed, approved or disapproved the contents of this press release.